Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature

Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment

(2013) Kathryn L. Burgio   ANNALS OF INTERNAL MEDICINE

Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms

(2010) Manish Gopal et al.   OBSTETRICS AND GYNECOLOGY

Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study

(2009) James G. Malone-Lee et al.   BJU INTERNATIONAL

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment

(2009) Steven E. Swift et al.   CLINICAL DRUG INVESTIGATION

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

(2009) J.-J. Wyndaele et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Clinical guidelines for overactive bladder

(2009) Osamu Yamaguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

Efficacy and tolerability of fesoterodine in women with overactive bladder

(2009) Peter K. Sand et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin

(2009) Peter K. Sand et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months

(2009) Rebecca G. Rogers et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Bother Related to Bladder Control and Health Care Seeking Behavior in Adults in the United States

(2009) Joshua S. Benner et al.   JOURNAL OF UROLOGY

Combined Effects of Behavioral Intervention and Tolterodine in Patients Dissatisfied With Overactive Bladder Medication

(2009) Carl G. Klutke et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study

(2009) David R. Staskin et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Extended-Release Oxybutynin in Combination With Tamsulosin for Treatment of Lower Urinary Tract Symptoms in Men: Randomized, Double-Blind, Placebo-Controlled Study

(2009) Scott A. MacDiarmid et al.   MAYO CLINIC PROCEEDINGS

Reviewing the ICS 2002 terminology report: The ongoing debate

(2009) Paul Abrams et al.   NEUROUROLOGY AND URODYNAMICS

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder

(2009) Laura T. Pizzi et al.   PHARMACOECONOMICS

Burden of Illness Associated With Lower Urinary Tract Symptoms Including Overactive Bladder/Urinary Incontinence

(2009) Hema Kannan et al.   UROLOGY

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

(2008) Steven A. Kaplan et al.   BJU INTERNATIONAL

Comparison of fesoterodine and tolterodine in patients with overactive bladder

(2008) Christopher R. Chapple et al.   BJU INTERNATIONAL

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

(2008) Karin S. Coyne et al.   BJU INTERNATIONAL

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

(2008) Linda Cardozo et al.   BJU INTERNATIONAL

Impact of fesoterodine on quality of life: pooled data from two randomized trials

(2008) Con J. Kelleher et al.   BJU INTERNATIONAL

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study

(2008) Michael B. Chancellor et al.   CLINICAL THERAPEUTICS

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms

(2008) Sender Herschorn et al.   CURRENT MEDICAL RESEARCH AND OPINION

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

(2008) Mark Speakman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER

(2008) Norman Zinner et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine??Clinical Use

(2008) Martin C Michel et al.   DRUG SAFETY

Symptom Bother and Health Care–Seeking Behavior among Individuals with Overactive Bladder

(2008) Debra E. Irwin et al.   EUROPEAN UROLOGY

Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size

(2008) Claus G. Roehrborn et al.   EUROPEAN UROLOGY

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

(2008) N. Zinner et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

(2008) M.-S Choo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder

(2008) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial

(2008) Mel Lauti et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

(2008) Rebecca Rogers et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Randomized, Placebo-Controlled Trial of the Cognitive Effect, Safety, and Tolerability of Oral Extended-Release Oxybutynin in Cognitively Impaired Nursing Home Residents with Urge Urinary Incontinence

(2008) Thomas E. Lackner et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study

(2008) Peter Dwyer et al.   NEUROUROLOGY AND URODYNAMICS

Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study

(2008) Roger R. Dmochowski et al.   UROLOGY

Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome

(2008) Vik Khullar et al.   UROLOGY

Treatment With Solifenacin Increases Warning Time and Improves Symptoms of Overactive Bladder: Results From VENUS, a Randomized, Double-Blind, Placebo-Controlled Trial

(2008) Mickey M. Karram et al.   UROLOGY